Search

Your search keyword '"Nephrosis, Lipoid genetics"' showing total 124 results

Search Constraints

Start Over You searched for: Descriptor "Nephrosis, Lipoid genetics" Remove constraint Descriptor: "Nephrosis, Lipoid genetics"
124 results on '"Nephrosis, Lipoid genetics"'

Search Results

1. TRPC6 knockdown-mediated ERK1/2 inactivation alleviates podocyte injury in minimal change disease via upregulating Lon peptidase 1.

2. Circulating RAC1 contributed to steroid-sensitive nephrotic syndrome: Mendelian randomization, single-cell RNA-sequencing, proteomic, and experimental evidence.

3. Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.

4. Shared genetic risk across different presentations of gene test-negative idiopathic nephrotic syndrome.

5. AMPK mediates regulation of glomerular volume and podocyte survival.

6. MicroRNAs in childhood nephrotic syndrome.

7. Minimal Change Disease With Nephrotic Syndrome Associated With Coronavirus Disease 2019 After Apolipoprotein L1 Risk Variant Kidney Transplant: A Case Report.

8. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.

9. The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis.

10. Soluble Vascular Cell Adhesion Molecule-1 Is Associated With Disease Activity in Adult-Onset Minimal Change Disease.

11. Each liver X receptor (LXR) type has a different purpose in different situations.

12. Vangl2, a planar cell polarity molecule, is implicated in irreversible and reversible kidney glomerular injury.

13. CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report.

14. Podocyte-Specific Induction of Krüppel-Like Factor 15 Restores Differentiation Markers and Attenuates Kidney Injury in Proteinuric Kidney Disease.

15. Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy.

16. Changes in DNA methylation in naïve T helper cells regulate the pathophysiological state in minimal-change nephrotic syndrome.

17. Minimal change nephrotic syndrome and prohibitin-2 gene polymorphism.

18. USP40 gene knockdown disrupts glomerular permeability in zebrafish.

19. Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.

20. Association of HLA-DR/DQ alleles and haplotypes with nephrotic syndrome.

21. Clinical and histological findings of autosomal dominant renal-limited disease with LMX1B mutation.

22. [ManNAc, a new therapeutic agent to reduce Angptl4-induced proteinuria in MCD].

23. Renal microRNA- and RNA-profiles in progressive chronic kidney disease.

24. Paraoxnase1 Gene Polymorphism in Childhood Idiopathic Nephrotic Syndrome.

25. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.

26. Comparison of Glomerular Transcriptome Profiles of Adult-Onset Steroid Sensitive Focal Segmental Glomerulosclerosis and Minimal Change Disease.

27. Alteration in the podoplanin-ezrin-cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome.

28. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease.

29. Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible.

30. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.

31. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.

32. Familial IPEX syndrome: different glomerulopathy in two siblings.

33. Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.

34. Urinary messenger RNA of the receptor activator of NF-kappaB could be used to differentiate between minimal change disease and membranous nephropathy.

35. CD3G gene defects in familial autoimmune thyroiditis.

36. CTLA4 polymorphisms in minimal change nephrotic syndrome in children: a case-control study.

37. The CTLA-4 +49GG genotype is associated with susceptibility for nephrotic kidney diseases.

38. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

39. Two new families with hereditary minimal change disease.

40. Mutational analysis of ACTN4, encoding α-actinin 4, in patients with focal segmental glomerulosclerosis using HRM method.

41. DNA methylation changes between relapse and remission of minimal change nephrotic syndrome.

42. [Family occurrence of steroid-sensitive idiopathic nephrotic syndrome].

43. [Correlation between Chinese medicine syndromes and the NPHS1 gene and NPHS2 gene polymorphism as well as corticosteroid sensitivity in patients with minimal change disease].

44. Evaluation of T-Cell receptor diversity in pediatric patients with minimal change nephrotic syndrome.

45. GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E.

46. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis.

47. Upregulation of nuclear factor-related kappa B suggests a disorder of transcriptional regulation in minimal change nephrotic syndrome.

48. TRPC6 gene variants in Czech adult patients with focal segmental glomerulosclerosis and minimal change disease.

49. DD genotype of ACE gene in boys: may it be a risk factor for minimal change nephrotic syndrome?

50. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.

Catalog

Books, media, physical & digital resources